SHARE THIS POST

VICTORIA, British Columbia, Feb. 02, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV:EMH) (OTCQX:EMHTF) announces that it has filed a second amended and restated final base shelf prospectus (the “Second Amended Prospectus”) with the securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador, amended and restated the amended and restated base shelf prospectus filed by the Company on July 13, 2017 (the “First Amended Prospectus”), which amended and restated the base shelf prospectus filed by the Company on January 25, 2017 (together with the First Amended Prospectus, the “Original Prospectus”) with such securities regulatory authorities.

As announced on February 10, 2017, April 20, 2017, April 21, 2017 and January 9, 2018, the Company has issued an aggregate of $55,940,673 of Securities (as defined below) under the Original Prospectus and therefore, prior to the filing of the Second Amended Prospectus, had an aggregate of $94,059,327 of Securities unallocated under the Original Prospectus. The Second Amended Prospectus will allow the Company, in the aggregate, to offer, from time to time, up to $250,000,000 of Securities of which $194,059,327 is unallocated of the date hereof during the period ending February 25, 2019 that the Amended Prospectus remains effective (the “Effective Period”).

The Second Amended Prospectus will enable the Company to make offerings of up to $250,000,000 of common shares, preferred shares, debt securities, warrants, units or subscription receipts of the Company (collectively, the “Securities”) or a combination thereof from time to time, separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the offering and as set out in an accompanying prospectus supplement during the Effective Period. The specific terms of any future offering will be established in a prospectus supplement to the Second Amended Prospectus, which supplement will be filed with the applicable Canadian securities regulatory authorities. The net proceeds from any sale of any securities will be used for purposes as set out in the applicable prospectus supplement. The Second Amended Prospectus also permits secondary offering of Securities by shareholders of the Company.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

A copy of the Second Amended Prospectus can be found under the Company’s profile on sedar.com or may be obtained from the Company upon written request from the contact below.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. (“Botanicals”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms, a partnership with Village Farms that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information regarding Emerald Health Therapeutics Inc., please visit www.emeraldhealth.ca for more information or contact:

Robert Hill, CFO (800) 757 3536 Ext. #722 invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to statements regarding the filing and effectiveness of any potential prospectus supplement; the amount and terms of any securities to be offered;, expansion of Emerald’s business; creation of strategic development opportunities; commercial operations; construction or conversion of production facilities; expected timing of any of the above matters; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics, Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the potential offering of any securities by the Company; uncertainty with respect to the completion of any future offering; the ability to obtain applicable regulatory approval for any contemplated offerings; the ability of the Company to negotiate and complete future funding transactions;, failure to obtain regulatory approval for closing of the proposed transaction or to meet the conditions set out in the Agreement; failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; Emerald’s ‘s historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in Emerald’s annual information form and other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.